Data from two seroprevalence studies and one comparative study of confirmatory algorithms were used to compare the costs and sensitivities of six algorithms for determining seropositivity to human immunodeficiency virus (HIV). We evaluated confirmatory strategies by using the CBC Recombigen HIV enzyme immunoassay (EIA; Cambridge BioScience, Worcester, Mass.) and immunoblotting followed by radioimmunoprecipitation assay to confirm indeterminate immunoblotting results with and without pooling of samples during screening. The least expensive algorithm was that in which sera were pooled during screening and EIA was used to confirm positive test results. The cost savings associated with this confirmatory test were greater when the prevalence of HIV infection was higher. Savings from pooling of sera for screen testing diminished as HIV prevalence increased. The sensitivity and specificity of EIA with respect to immunoblotting and radioimmunoprecipitation assay were estimated to be 0.9992 and 0.9977, respectively. We found that the implementation of pooling during screening and the use of ELI as the confirmatory test do not affect the statistical reliability of estimates of seropositivity but do result in considerable cost savings.
Accurate prediction of the extent and impact of the human immunodeficiency virus (HIV)-AIDS epidemic requires that proper epidemiological studies be completed. Volunteer studies are exquisitely sensitive to self-selection bias. For this reason, investigators have turned to unlinked seroprevalence surveys in which large numbers of specimens left over from studies that used routinely collected samples are tested after identifying information has been removed. However, such studies are costly because of the large numbers of screening tests needed and the requisite confirmatory assay for screen test-positive samples. Alternative strategies have been developed to reduce the costs of these large serosurveys, including the pooling of samples prior to testing (1, 6, 8) and the use of less expensive tests as the supplemental assay in lieu of the more expensive immunoblotting, immunofluorescence assay, or radioimmunoprecipitation assay (RIPA) (2, 5, 12, 13, 15) . In this report, we compare the costs of six algorithms for testing for HIV seropositivity. The following three strategies for confirming screen test-reactive sera were compared: CBC Recombigen HIV enzyme immunoassay (EIA; Cambridge BioScience, Worcester, Mass.), immunoblotting with RIPA to confirm indeterminate immunoblotting results, and immunoblotting with repeat enzymelinked immunosorbent assay (ELISA) and immunoblottings at a later visit to confirm indeterminate results. These three strategies for confirming repeat screen test-positive samples are illustrated in Fig. 1 . Each of the strategies was studied with and without pooling of samples during screening for a total of six algorithms. We demonstrate that the combination of pooling and then the use of the EIA for confirming screen test-reactive samples results in significant cost reductions without impairing the statistical reliability of the study. * Corresponding author.
MATERIALS AND METHODS
Study populations. We used data from three studies to compare confirmatory tests and to evaluate the effectiveness of pooling in reducing the costs of screen testing.
In the first study, we compared two confirmatory testing strategies using 2,212 samples received consecutively at the Federal Center for AIDS Laboratories, the Canadian National Reference Laboratory for HIV (9) . Sera which were repeatedly positive by ELISA (Genetic Systems Corporation, Seattle, Wash.) were verified as being antibody positive by immunoblotting. Western blots (immunoblots) were performed by using the human T-cell lymphotropic virus type III Western blot kit (Du Pont Co., Wilmington, Del.). Samples which demonstrated antibody reactivity to env and gag proteins were considered Western blot positive. Samples were negative if no bands were seen on the Western blot and were indeterminate if they failed to meet the criteria of either a positive or a negative sample. Sera which were antibody indeterminate by immunoblotting were then tested by RIPA. Samples reported as immunoblot or RIPA positive were considered to be antibody positive. Concomitantly, all ELISA-positive sera were tested by the EIA according to the manufacturer's instructions. The EIA did not yield any "gray zone" results. Instead, all results were either positive or negative. In the present study, the prevalence of HIV antibody positivity was nearly 50%, because at that time we were testing sera collected from high-risk individuals for specific investigations.
The second study was a prevalence study of childbearing women in Quebec. Over a 3-year period, 199,962 heel prick samples were collected as dried blood spots from newborn children and were screened for HIV antibody (7 
RESULTS
Sensitivity and specificity. We estimated the sensitivity and specificity of the EIA as a confirmatory test compared with the "gold standard" algorithm of immunoblotting and RIPA using data from studies of high-risk individuals and childbearing women. In the study of high-risk individuals, the sensitivity and specificity of the EIA were calculated to be 99.9 and 99.7%, respectively, as reported previously (3) .
Of the 199,962 heel prick specimens collected from newborns, 417 were repeatedly reactive by ELISA and were retested by immunoblotting and EIA. One hundred twentyfive samples were antibody positive by both methods. Fiftyfour samples with immunoblotting-indeterminate results were retested by RIPA and were found to be negative, resulting in a total of 292 samples which were antibody negative by both methods. There were no samples with discordant results. In the present study, the EIA was found to have 100% sensitivity and specificity when compared with immunoblotting and RIPA combined.
When results from the two studies were aggregated, 1,294 samples were antibody positive by both methods, 1,330 samples were antibody negative by both methods, 3 samples were positive by the EIA but negative by immunoblotting and RIPA, and 1 sample was negative by the EIA but positive by immunoblotting and RIPA. By using the combined data, the sensitivity and specificity of the EIA with respect to immunoblotting and RIPA were calculated to be 0.9992 and 0.9977, respectively, with corresponding 95% confidence intervals of 0.998 and 1 and 0.995 and 1.
The results from three samples which were found to be positive by EIA but negative by immunoblotting and RIPA may have been due to the imperfect specificity of the immunoblotting technique. If, however, the samples that gave these discordant results were cross-contaminated during processing, as suspected, these results would then represent a worst-case scenario for the performance of the EIA. The discordant specimens could not be retested since they were from foreign Red Cross blood donors.
The sensitivity of the proposed algorithm is the product of the sensitivity of the ELISA and the sensitivity of the EIA. The specificity of the proposed algorithm is 1 -(1 -specificity of ELISA). were assayed individually, indicating that the pooling did not adversely affect the specificity of the Organon Teknika test kit. Given that 489 of 40,090 samples tested were antibody positive, we would have expected 463 pools to test positive according to the formula presented in Materials and Methods. Fewer pools than expected tested positive, however, as a result of the clustering of positive results at one of the laboratory sites.
Positive predictive value. The positive predictive value, i.e., the probability that the results of the proposed algorithm agree with those of the gold standard, is of considerable interest. This probability depends on the sensitivity and specificity of the test and on the prevalence of the disease in the population tested. We calculated the positive predictive value of the proposed algorithm for a range of prevalences and specificities. Since the sensitivity has the least influence on the positive predictive value, we left this constant at 0.997. The results in Table 3 show that a positive test result from the proposed algorithm is highly predictive of HIV disease for a range of prevalences and specificities and has no appreciable impact on estimates derived from large seroprevalence studies. In the worst case, in which the positive predictive value is 0.91, the seroprevalence derived from the survey would overestimate the gold standard infection by only about 10%.
DISCUSSION
We have not discussed the indirect immunofluorescence test in this report because this procedure is not used exten- A considerable portion of the cost associated with pooling of sera for screen testing results from the need to test samples individually from each pool which tests positive. In large seroprevalence studies, it may be possible to minimize the number of pools testing positive by pooling samples thought to be at higher risk of seropositivity separately. As shown in the British Columbia seroprevalence study (14) , in which seroprevalence varied by geographic area, pooling of samples by laboratory site resulted in many fewer pools testing positive than would have been expected from the overall estimated prevalence.
There may be limitations of pooling sera prior to testing. In a study of samples received in a national reference laboratory, typing by using a human genetic marker, the variable number of tandem repeats, showed that 1% of the samples were mislabeled (11) . Other studies have found similar rates of mislabeling (3) . Pooling may increase the rate of misidentification because of the increased handling of samples by laboratory staff. In addition, the considerable manipulations required to construct the pools may result in the occasional omission of a sample, and thus a decrease in the sensitivity of the proposed algorithm. Another concern is the cross-contamination of samples as a result of poor laboratory practices as observed in several large seroprevalence studies (10) . Laboratory practices which can result in the cross-contamination of samples include the repeated use of the same pipette tip and the too vigorous shaking of racks of open tubes of sera. Lastly, since seroprevalence studies often use residual samples from routine laboratory testing, the integrity of the sera may not be retained. Errors such as those described here could occur with pooling protocols if sufficient detail is not followed in either the laboratory that collects the samples or the laboratory performing the HIV antibody assays. For these reasons, laboratories which use pooling for cost saving purposes must have strong quality assurance programs in place prior to embarking on this strategy.
Pooling may also result in decreased sensitivity and specificity of the proposed algorithm for reasons other than laboratory procedures. Sensitivity may be decreased if antibody-positive samples with low reactivity in the EIA are undetected in pools because the optical density of the lx -diluted antibody-positive sample falls below the established gray zone of the screening test (10% below the cutoff of the EIA). Specificity could be adversely affected if nonspecific interactions between individual samples during pooling cause false-positive results. Such interactions were not found to occur in the present study, however. In addition, the use of the EIA as the confirmatory assay eliminates the well-known difficulty of the relatively low specificity of immunoblotting (4) .
Despite the concerns that we have raised here, we recommend the use of pooling during the screening of samples for HIV antibody and the use of the Recombigen ETA as the confirmatory assay. The potential loss in sensitivity because of the low levels of reactivity of the samples and the potential loss of specificity because of nonspecific interactions between samples is minimal compared with the loss in these measures because of poor laboratory practices. We feel that with proper implementation of strict laboratory practices, such errors can be eliminated and that the possibility of additional errors resulting from the pooling process can be minimized.
